ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC RESPONSE AND LONG-TERM CLINICAL OUTCOMES: RESULTS FROM PHASE 2 MIRIKIZUMAB TRIAL IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE
Vipul Jairath 1
Marijana Protic 2
Walter Reinisch 3
Gert De Hertogh 4
Noam Harpaz 5
Rish Pai 6
Zhantao Lin 6
Rebecca Hozak 6
Hilde Carlier 6
Fernando Magro 7
1 Western University, London, Canada
2 Eli Lilly and Company, Indianapolis, United States
3 Medical University of Vienna, Wien, Austria
4 University Hospital Leuven, Leuven, Belgium
5 Icahn School of Medicine at Mount Sinai, New York, United States
6 Mayo Clinic, Scottsdale, United States
7 Centro Hospitalar São João, Porto, Portugal
Topic
Endoscopy, Histopathology, IBD
Session
IL-23-Blockers in IBD: Part 2
Conference
UEG Week Copenhagen 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]